Enhanced pro-apoptotic activity of rituximab through IBTK silencing in non-Hodgkin lymphoma B-cells

Enhanced pro-apoptotic activity of rituximab through IBTK silencing in non-Hodgkin lymphoma B-cells

Rituximab is a commonly used chemotherapeutic drug for patients with aggressive lymphomas, such as non-Hodgkin’s lymphoma (NHL). Currently, the combination of Rituximab and chemotherapy (R-CHOP) stands as the most prevalent first-line therapy for NHL. Nevertheless, the development of new therapeutic...

Full description

Bibliographic Details
Main Authors: Eleonora Vecchio, Rossana Marino, Selena Mimmi, Camilla Canale, Carmen Caiazza, Alessandro Arcucci, Maria Rosaria Ruocco, Marco Schiavone, Gianluca Santamaria, Camillo Palmieri, Enrico Iaccino, Massimo Mallardo, Ileana Quinto, Giuseppe Fiume
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
rituximab
non-Hodgkin’s lymphoma
MYC
IBTK
apoptosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1339584/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1339584/full

Similar Items